Imatinib mesylate treatment for platelet-derived growth factor receptor alfa-positive choroid plexus carcinoma
AbstractWe herein report a female child with choroid plexus carcinoma treated with standard dose of imatinib at disease recurrence. This patient failed initial twice-surgical resections, central nervous system (CNS) irradiation, and adjuvant chemotherapies and high-dose thiotepa and melphalan with auto peripheral blood stem cell rescue. Finally, imatinib treatment was undergone as a palliative setting, however the tumor did not reduce and the patient died of tumor bleedings. We consider that the reasons for the failure are as follows: i) adequate CNS level of imatinib were not obtained because of the blood brain barrier, ii) the lack of plateletderived growth factor receptor beta expression in our case may have a crucial role.
PlumX Metrics provide insights into the ways people interact with individual pieces of research output (articles, conference proceedings, book chapters, and many more) in the online environment. Examples include, when research is mentioned in the news or is tweeted about. Collectively known as PlumX Metrics, these metrics are divided into five categories to help make sense of the huge amounts of data involved and to enable analysis by comparing like with like.
- Abstract views: 683
- PDF: 503
- HTML: 171
Copyright (c) 2012 Chihiro Kawakami, Akiko Inoue, Kimitaka Takitani, Motomu Tsuji, Kimiko Wakai, Hiroshi Tamai
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.